Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells

被引:0
|
作者
F. Tamanoi
C.-L. Gau
C. Jiang
H. Edamatsu
J. Kato-Stankiewicz
机构
[1] Department of Microbiology and Molecular Genetics,
[2] Jonsson Comprehensive Cancer Center,undefined
[3] University of California Los Angeles,undefined
[4] California 90095-1489 (USA),undefined
[5] Fax: +1 310 206 5231,undefined
[6] e-mail: fuyut@microbio.ucla.edu,undefined
关键词
Key words. Protein farnesylation; farnesyltransferase inhibitor; cell cycle; apoptosis.;
D O I
暂无
中图分类号
学科分类号
摘要
Protein farnesylation, catalyzed by protein farnesyltransferase, plays important roles in the membrane association and protein-protein interaction of a number of eukaryotic proteins. Recent development of farnesyltransferase inhibitors (FTIs) has led to further insight into the biological significance of farnesylation in cancer cells. A number of reports point to the dramatic effects FTIs exert on cancer cells. In addition to inhibiting anchorage-independent growth, FTIs cause changes in the cell cycle either at the G1/S or at the G2/M phase. Furthermore, induction of apoptosis by FTIs has been reported. FTIs also affects the actin cytoskeleton and cell morphology. This review summarizes these reports and discusses implications for farnesylated proteins responsible for these FTI effects.
引用
收藏
页码:1636 / 1649
页数:13
相关论文
共 50 条
  • [31] Effects of protein kinase and phosphatase inhibitors on the growth of human prostatic cancer cells
    Konno, S
    Cherry, J
    Tazaki, H
    Mallouh, C
    Chiao, JW
    MEDICAL SCIENCE RESEARCH, 1997, 25 (05): : 353 - 354
  • [32] Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors
    Verstraeten, Valerie L. R. M.
    Ji, Julie Y.
    Cummings, Kiersten S.
    Lee, Richard T.
    Lammerding, Jan
    AGING CELL, 2008, 7 (03): : 383 - 393
  • [33] Bisubstrate analog inhibitors of protein farnesyltransferase
    Musa, Musa M.
    Distefano, Mark D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [34] Farnesylation of Pex19p is not essential for peroxisome biogenesis in yeast and mammalian cells
    I. M. K. Vastiau
    E. A. Anthonio
    M. Brams
    C. Brees
    S. G. Young
    S. Van de Velde
    R. J. A. Wanders
    G. P. Mannaerts
    M. Baes
    P. P. Van Veldhoven
    M. Fransen
    Cellular and Molecular Life Sciences CMLS, 2006, 63 : 1686 - 1699
  • [35] NONFARNESYLATED TETRAPEPTIDE INHIBITORS OF PROTEIN FARNESYLTRANSFERASE
    GOLDSTEIN, JL
    BROWN, MS
    STRADLEY, SJ
    REISS, Y
    GIERASCH, LM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (24) : 15575 - 15578
  • [36] Farnesylation of Pex19p is not essential for peroxisome biogenesis in yeast and mammalian cells
    Vastiau, I. M. K.
    Anthonio, E. A.
    Brams, M.
    Brees, C.
    Young, S. G.
    Van de Velde, S.
    Wanders, R. J. A.
    Mannaerts, G. P.
    Baes, M.
    Van Veldhoven, P. P.
    Fransen, M.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (14) : 1686 - 1699
  • [37] Methionine Aminopeptidase Inhibitors in Mammalian Cells
    Condic, Natalia
    Ramtahal, Cassandra
    Boukari, Jamila
    Croes, Alex
    Nguyen, Calvin
    Alvarez, Melissa
    Olaleye, Omonike
    Rosell, Rosemarie
    FASEB JOURNAL, 2020, 34
  • [38] BISUBSTRATE INHIBITORS OF FARNESYLTRANSFERASE - A NOVEL CLASS OF SPECIFIC INHIBITORS OF RAS TRANSFORMED-CELLS
    MANNE, V
    YAN, N
    CARBONI, JM
    TUOMARI, AV
    RICCA, CS
    BROWN, JG
    ANDAHAZY, ML
    SCHMIDT, RJ
    PATEL, D
    ZAHLER, R
    WEINMANN, R
    DER, CJ
    COX, AD
    HUNT, JT
    GORDON, EM
    BARBACID, M
    SEIZINGER, BR
    ONCOGENE, 1995, 10 (09) : 1763 - 1779
  • [39] Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells
    Aratani, Y
    Andoh, T
    Koyama, H
    MUTATION RESEARCH-DNA REPAIR, 1996, 362 (02): : 181 - 191
  • [40] Protein Expression in Mammalian Cells
    Lacinova, Lubica
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2012, 31 (03) : 352 - 353